Chondroitin Sulfate Market - Growth, Trends, and Forecast (2020 - 2025)
|出版商||Mordor Intelligence LLP||商品編碼||921900|
|出版日期||內容資訊||英文 111 Pages
|全球硫酸軟骨素市場:成長，趨勢，及預測(2020年∼2025年) Chondroitin Sulfate Market - Growth, Trends, and Forecast (2020 - 2025)|
|出版日期: 2020年01月01日||內容資訊: 英文 111 Pages||
A high prevalence of osteoarthritis is the major driving factor for the growth of the Chondroitin Sulfate market. The National Institute of Health (NIH) stated in its report that over 30 million adults in the United States were diagnosed with osteoarthritis (OA) in the year 2017. The aging of the population and increasing obesity seen in all age groups are the prime causes of osteoarthritis in the country. Furthermore, increasing applications of chondroitin sulfate in various treatments is boosting the overall market growth for Chondroitin Sulfate globally. Not only in the treatment of osteoarthritis, but Chondroitin sulfate is also used in eye drops to treat dry eyes. Furthermore, it is also used in the solution to preserve cornea while transplantation during the cataract surgery. In April 2015, Santen Pharmaceutical Co., Ltd. launched New Sante de U α, an OTC eye drop with Chondroitin sulfate sodium as an active ingredient for relieving eye fatigue and preventing eye disease.
As per the scope of the report, Chondroitin sulfate is a glycosaminoglycan which is a major component of the extracellular matrix (ECM) of many connective tissues, including cartilage, bone, skin, ligaments, and tendons. In supplements, chondroitin sulfate usually comes from animal cartilage.
Pharmaceuticals segment holds significant market share
North America holds the largest market share in Global Chondroitin Sulfate Market
The well-established pharmaceutical industry in the North America region and increasing USFDA approvals for chondroitin sulfate can be credited to the growth of the Chondroitin Sulfate Market in the region. High prevalence of osteoarthritis and increased use of cholesterol in cataract surgery and formulations for a drop in the eye are also a few factors that are enhancing the growth in North America. In November 2017, Gnosis launched the first dietary supplements with Mythocondro, the unique 100% vegan chondroitin sulfate similar to human synovial fluid into the USA market.
The Asia Pacific is estimated to be the fastest-growing region during the forecast period owing to the high incidence of osteoarthritis and growing awareness about the chondroitin sulfate applications in personal care and nutritional supplements.
The market is moderately competitive due to the presence of many manufacturers. Competition in the market is moderate due to the increasing investments in R&D for product innovation and the increasing efficiency of the product by launching new products into the market. For instance, in April 2019 Fidia, launched CartiJoint FORTE, its first product in the dietary supplement category in the USA. CartiJoint FORTE also contains glucosamine hydrochloride and chondroitin sulfate. With the rising prevalence of osteoarthritis and other indications where Chondroitin Sulfate is used, it is believed that few small to mid-sized companies will penetrate the market in the future.